A Phase 2 interventional study of GWP42003 and GWP42003 in Dyslipidemias and Diabetes Mellitus, Type 2, sponsored by Jazz Pharmaceuticals. Completed at 5 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-18.
Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Dyslipidemias with a site in United Kingdom — 6 open to participants now, 9 under way, 3 of them phase 3. Dyslipidemias · United Kingdom.
Among the 55 studies in Dyslipidemias with a site in United Kingdom, this one is the 35th largest by enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2010, is one of 4 in phase 2, and was the 23rd registered.
1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.
Browse Dyslipidemias studies →6 of the 55 studies in Dyslipidemias with a site in United Kingdom are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Austria and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 20 more countries
Ages 6–11
CRISPR Therapeutics AG · Sites in United Kingdom, United States, Australia and 1 more country
Ages 18–75
Newcastle University · Sites in United Kingdom, Belgium, Finland and 9 more countries
Ages 18–100
Liverpool John Moores University · Sites in United Kingdom
Ages 25–60 · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 5 · Phase 3 28 · Phase 4 3
First in 2001; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 100 across 987 interventional studies indexed under Dyslipidemias.
Median enrollment 342 across the 48 interventional studies, 847 across the 7 observational. Of the 44 that completed or were terminated, 22 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 55 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 1 study filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
4 of the studies in Dyslipidemias with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05399992Novartis PharmaceuticalsStudy Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | 2026-11-23 |
| NCT07474233Liverpool John Moores UniversityAssociations Between Dietary Patterns, LDL Aggregation, and Cardiometabolic Health | 2027-05 |
| NCT07462871Liverpool John Moores UniversityComparative Effects of Carnivore and Mediterranean-style Diets on LDL Aggregation and Cardiometabolic Health | 2027-06 |
| NCT07491172CRISPR Therapeutics AGA Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Dyslipidemias with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This 15-19 week study is being conducted by GW Pharma Ltd as a pilot study in order to determine the efficacy and safety of two cannabinoids: GWP42004 and GWP42003 alone, or in combination in patients with Type 2 diabetes. This is the first study to determine whether the study medications have a positive benefit for subjects on their cholesterol levels, body weight, liver fat content and other metabolic parameters compared with a placebo medication.
In this study there was a 1-5 week baseline period followed by a 13 week treatment period, and a one week follow-up. Eligible subjects entered the study at a screening visit (Visit 1) before returning for randomisation (Visit 2, Day 1). At the discretion of the investigator (based on individual subjects), Visit 1 could be split into two separate visits (Visits 1A and B) to allow a 21-day washout period of prohibited medications prior to blood sampling for eligibility. Further outpatient study visits (for assessment purposes) took place at the study site at the end of Week 4 of treatment (Visit 3, Day 29), and at the overall end of treatment at Week 13 (Visit 5, Day 92). A telephone assessment was also performed at Day 57 (Visit 4) and at Week 14 (Visit 6, Day 99) for safety follow-up purposes.
During the 13 week randomised treatment phase, subjects received blinded, oral doses of their allocated randomised treatment twice daily. Treatment was self-administered on an outpatient basis, once in the morning and once in the evening for 13 weeks. Subjects were instructed to time study medication to 30 minutes before breakfast and evening meals.
Physical and metabolic parameters were assessed before, during and after treatment to evaluate clinical response. Diabetic and dyslipidaemic medication usage (where applicable), and appetite 0-10 NRS data were collected daily during the treatment period, using the study diary.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any known or suspected history of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contains GWP42004 5 mg and placebo (excipients only)
Drug: GWP42004 · Drug: Placebo
Contains 5 mg each of GWP42003 and GWP42004
Drug: GWP42003 · Drug: GWP42004
Contains 100 mg GWP42003 and 5 mg GWP42004
Drug: GWP42003 · Drug: GWP42004
Contains excipients only
Drug: Placebo
Contains 100 mg GWP42003 and placebo (excipients only)
Drug: GWP42003 · Drug: Placebo
The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum High Density Lipoprotein cholesterol. An increase from baseline to the end of treatment, a positive value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean High Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of High Density Lipoprotein cholesterol by ultracentrifugation. An increase from baseline to the end of treatment, a positive value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Serum Total Cholesterol Concentration After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum total cholesterol. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Total Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum total cholesterol by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Serum Low Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Low Density Lipoprotein cholesterol. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of Low Density Lipoprotein cholesterol by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Serum High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio After 91 Days (13 Weeks) of Treatment
An increase from baseline (i.e. a positive value) to the end of treatment in the High Density Lipoprotein : Low Density Lipoprotein cholesterol ratio indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
An increase from baseline (i.e. a positive value) to the end of treatment in the High Density Lipoprotein : Low Density Lipoprotein cholesterol ratio indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Very Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of Very Low Density Lipoprotein cholesterol by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Serum Triglyceride Concentration After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum triglyceride concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Triglyceride Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of triglyceride concentrations by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Serum Apolipoprotein A Concentration After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Apolipoprotein A. An increase from baseline to the end of treatment, a positive value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Serum Apolipoprotein B Concentration After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Apolipoprotein B. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Serum Apolipoprotein B : Apolipoprotein A Ratio After 91 Days (13 Weeks) of Treatment
A decrease from baseline to the end of treatment (i.e. a negative value) in the Apolipoprotein B : Apolipoprotein A ratio indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Serum Non-Esterified Fatty Acid Concentration After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Non-Esterified Fatty Acid concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Fasting Glucose Concentration After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of fasting glucose concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Fructosamine Concentration After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of fructosamine concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Glycated Haemoglobin Concentration After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of glycated haemoglobin concentrations. At both time points, values were calculated as a percentage of total haemoglobin. A decrease from baseline to the end of treatment in base per cent values, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Glucose Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test [OGTT])
A two-hour OGTT was performed to investigate the rate of glucose metabolism or clearance from the blood with treatment. Blood samples were taken at -15 and 0 minutes prior to a glucose drink and at 30, 60, 90, 120 and 180 minutes post drink. The OGTT measured the change from baseline in serum glucose levels at two hours (120 minutes) compared to 0 minutes. The extent of the elevation in blood glucose levels following a glucose drink were compared between baseline and the end of treatment. A reduction in the elevation of serum glucose levels at the end of treatment (i.e. a negative value) indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Insulin Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test)
At baseline and the end of treatment, blood samples were taken at -15 and 0 minutes prior to a glucose drink and at 30, 60, 90, 120 and 180 minutes post drink. The OGTT measured the change from baseline in serum insulin levels at two hours (120 minutes) compared to 0 minutes. The extent of the elevation in blood glucose levels following a glucose drink were compared between baseline and the end of treatment. An increase in the elevation of serum insulin levels from baseline to the end of treatment (i.e. a positive value) indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Fasting Insulin Concentration After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of fasting insulin concentrations. An increase from baseline to the end of treatment, a positive value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean C-peptide Concentration After 91 Days (13 Weeks) of Treatment
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of C-peptide concentrations. An increase from baseline to the end of treatment, a positive value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Insulin Resistance Measured by Homeostasis Model Assessment 2 (HOMA2-IR) After 91 Days (13 Weeks) of Treatment
Changes from baseline to the end of treatment in mean insulin resistance were calculated by HOMA2-IR. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin resistance, which is the reciprocal of insulin sensitivity (%S)(100/%S) as a percentage of a normal reference population (normal young adults). A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Insulin Sensitivity Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment
Changes from baseline to the end of treatment in mean insulin sensitivity were calculated by HOMA2. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). An increase from baseline to the end of treatment, a positive value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Insulin B Cell Function Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment
Changes from baseline to the end of treatment in mean insulin B Cell Function were calculated by HOMA2. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate beta cell function (%B) as a percentage of a normal reference population (normal young adults). An increase from baseline to the end of treatment, a positive value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Body Mass Index After 91 Days (13 Weeks) of Treatment
Body Mass Index was calculated at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Waist-to-hip Ratio After 91 Days (13 Weeks) of Treatment
Subject's waist-to-hip ratios were calculated at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Body Weight After 91 Days (13 Weeks) of Treatment
Subject's body weights were measured at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Waist Measurement After 91 Days (13 Weeks) of Treatment
Subjects' waist measurements were taken at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Hip Measurement After 91 Days (13 Weeks) of Treatment
Subjects' hip measurements were taken at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Visceral Abdominal Fat After 91 Days (13 Weeks) of Treatment
Visceral Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scans were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Subcutaneous Abdominal Fat After 91 Days (13 Weeks) of Treatment
Subcutaneous Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scans were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Total Abdominal Fat After 91 Days (13 Weeks) of Treatment
Total Abdominal Fat was measured by magnetic resonance imaging, and the results of the scans were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Internal Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment
Internal Non-Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Subcutaneous Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment
Subcutaneous Non-Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Total Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment
Total Non-Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Total Internal Fat After 91 Days (13 Weeks) of Treatment
Total Internal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Total Subcutaneous Fat After 91 Days (13 Weeks) of Treatment
Total Subcutaneous Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Total Fat After 91 Days (13 Weeks) of Treatment
Total Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Abdominal Adiposity After 91 Days (13 Weeks) of Treatment
Abdominal Adiposity was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean % Liver Fat After 91 Days (13 Weeks) of Treatment
Percentage liver fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment in base per cent values, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
The Change From Baseline in Mean Appetite 0-10 Numerical Rating Scale Score After 91 Days (13 Weeks) of Treatment
Subjects scored their appetite daily using an appetite 0-10 numerical rating scale score where 0 = no appetite (don't feel hungry) and 10 = maximum appetite (completely hungry all the time). The mean change from baseline to the end of treatment in scores were calculated. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
Time frame: Baseline (Day 1) and End of treatment (Day 92)
Adverse Events as a Measure of Patient Safety
The incidence of treatment-emergent adverse events was recorded for the study duration, and the number of patients who experienced an adverse event is presented.
Time frame: Day 1 - Day 92
The Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment
The BDI-II is a 21 question, multiple choice, self-reported inventory, and is one of the most widely used instruments for measuring the severity of depression. The 21 questions or items each had four possible responses. Each response was assigned a score ranging from zero to three, indicating the severity of the symptom, with a total possible score ranging from zero to 63. A score between zero and 13 indicates 'minimal depression'. A score between 14 and 19 indicates 'mild depression'. A score between 20 and 28 indicates 'moderate depression', and a score between 29 and 63 indicates 'severe depression'. As such, an increase from baseline to the end of treatment, a positive value, indicates a deterioration.
Time frame: Baseline (Day 1) and the End of Treatment (Day 92)
| Milestone | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| Started | 11 | 12 | 13 | 12 | 14 |
| Completed | 11 | 10 | 12 | 10 | 13 |
| Not completed | 0 | 2 | 1 | 2 | 1 |
| Withdrew: Adverse event | 0 | 2 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum High Density Lipoprotein cholesterol. An increase from baseline to the end of treatment, a positive value, indicates an improvement.
| mmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment | 0.00 ± 0.09 | 0.04 ± 0.07 | -0.04 ± 0.14 | 0.00 ± 0.14 | 0.02 ± 0.09 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of High Density Lipoprotein cholesterol by ultracentrifugation. An increase from baseline to the end of treatment, a positive value, indicates an improvement.
| mmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean High Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment | -0.04 ± 0.12 | -0.06 ± 0.08 | -0.11 ± 0.08 | -0.01 ± 0.16 | -0.02 ± 0.11 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum total cholesterol. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| mmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Serum Total Cholesterol Concentration After 91 Days (13 Weeks) of Treatment | -0.53 ± 0.78 | -0.27 ± 0.32 | -0.22 ± 0.50 | -0.13 ± 0.44 | -0.09 ± 0.39 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum total cholesterol by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| mmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Total Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment | -0.12 ± 0.83 | -0.23 ± 0.28 | -0.11 ± 0.52 | -0.11 ± 0.45 | -0.16 ± 0.33 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Low Density Lipoprotein cholesterol. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| mmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Serum Low Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment | -0.29 ± 0.62 | -0.13 ± 0.36 | -0.11 ± 0.40 | -0.02 ± 0.50 | 0.07 ± 0.33 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of Low Density Lipoprotein cholesterol by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| mmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment | -0.03 ± 0.49 | -0.16 ± 0.26 | -0.08 ± 0.43 | -0.08 ± 0.41 | -0.06 ± 0.19 |
An increase from baseline (i.e. a positive value) to the end of treatment in the High Density Lipoprotein : Low Density Lipoprotein cholesterol ratio indicates an improvement.
| ratio | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Serum High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio After 91 Days (13 Weeks) of Treatment | 0.03 ± 0.11 | 0.04 ± 0.05 | -0.02 ± 0.08 | 0.02 ± 0.09 | 0.01 ± 0.06 |
An increase from baseline (i.e. a positive value) to the end of treatment in the High Density Lipoprotein : Low Density Lipoprotein cholesterol ratio indicates an improvement.
| ratio | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio by Ultracentrifugation After 91 Days (13 Weeks) of Treatment | -0.01 ± 0.11 | 0.00 ± 0.05 | -0.02 ± 0.08 | 0.03 ± 0.12 | 0.01 ± 0.06 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of Very Low Density Lipoprotein cholesterol by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| mmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Very Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment | -0.06 ± 0.37 | -0.01 ± 0.16 | 0.08 ± 0.19 | -0.02 ± 0.24 | -0.08 ± 0.31 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum triglyceride concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| mmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Serum Triglyceride Concentration After 91 Days (13 Weeks) of Treatment | -0.47 ± 0.54 | 0.14 ± 0.28 | 0.09 ± 0.55 | 0.09 ± 0.66 | -0.12 ± 0.80 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of triglyceride concentrations by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| mmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Triglyceride Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment | -0.16 ± 0.56 | 0.12 ± 0.26 | 0.16 ± 0.34 | 0.05 ± 0.59 | -0.03 ± 0.74 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Apolipoprotein A. An increase from baseline to the end of treatment, a positive value, indicates an improvement.
| umol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Serum Apolipoprotein A Concentration After 91 Days (13 Weeks) of Treatment | -2.86 ± 8.84 | -3.51 ± 10.88 | -4.92 ± 6.04 | 0.64 ± 11.32 | -3.41 ± 6.22 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Apolipoprotein B. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| umol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Serum Apolipoprotein B Concentration After 91 Days (13 Weeks) of Treatment | -0.19 ± 0.84 | 0.18 ± 0.51 | 0.11 ± 0.53 | 0.08 ± 0.66 | 0.16 ± 0.42 |
A decrease from baseline to the end of treatment (i.e. a negative value) in the Apolipoprotein B : Apolipoprotein A ratio indicates an improvement.
| ratio | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Serum Apolipoprotein B : Apolipoprotein A Ratio After 91 Days (13 Weeks) of Treatment | -0.01 ± 0.23 | 0.07 ± 0.15 | 0.08 ± 0.13 | 0.01 ± 0.14 | 0.07 ± 0.12 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Non-Esterified Fatty Acid concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| mmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Serum Non-Esterified Fatty Acid Concentration After 91 Days (13 Weeks) of Treatment | 0.06 ± 0.17 | -0.03 ± 0.23 | -0.05 ± 0.30 | -0.02 ± 0.18 | 0.01 ± 0.15 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of fasting glucose concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| mmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Fasting Glucose Concentration After 91 Days (13 Weeks) of Treatment | -0.23 ± 2.02 | 0.44 ± 2.00 | 0.41 ± 0.82 | -0.76 ± 1.00 | 0.38 ± 1.15 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of fructosamine concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| umol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Fructosamine Concentration After 91 Days (13 Weeks) of Treatment | 2.8 ± 42.06 | 14.5 ± 29.53 | -2.6 ± 20.41 | 1.1 ± 11.68 | 9.5 ± 19.68 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of glycated haemoglobin concentrations. At both time points, values were calculated as a percentage of total haemoglobin. A decrease from baseline to the end of treatment in base per cent values, a negative value, indicates an improvement.
| percent | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Glycated Haemoglobin Concentration After 91 Days (13 Weeks) of Treatment | 0.14 ± 1.41 | 0.16 ± 0.44 | 0.08 ± 0.44 | -0.03 ± 0.22 | 0.31 ± 0.54 |
A two-hour OGTT was performed to investigate the rate of glucose metabolism or clearance from the blood with treatment. Blood samples were taken at -15 and 0 minutes prior to a glucose drink and at 30, 60, 90, 120 and 180 minutes post drink. The OGTT measured the change from baseline in serum glucose levels at two hours (120 minutes) compared to 0 minutes. The extent of the elevation in blood glucose levels following a glucose drink were compared between baseline and the end of treatment. A reduction in the elevation of serum glucose levels at the end of treatment (i.e. a negative value) indicates an improvement.
| mmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Glucose Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test [OGTT]) | -0.07 ± 1.89 | 1.09 ± 3.81 | -0.78 ± 1.51 | 0.22 ± 1.85 | 0.42 ± 1.44 |
At baseline and the end of treatment, blood samples were taken at -15 and 0 minutes prior to a glucose drink and at 30, 60, 90, 120 and 180 minutes post drink. The OGTT measured the change from baseline in serum insulin levels at two hours (120 minutes) compared to 0 minutes. The extent of the elevation in blood glucose levels following a glucose drink were compared between baseline and the end of treatment. An increase in the elevation of serum insulin levels from baseline to the end of treatment (i.e. a positive value) indicates an improvement.
| pmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Insulin Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test) | 80.9 ± 223.91 | -156.6 ± 358.53 | -193.5 ± 232.17 | 83.5 ± 427.94 | -40.8 ± 475.88 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of fasting insulin concentrations. An increase from baseline to the end of treatment, a positive value, indicates an improvement.
| pmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Fasting Insulin Concentration After 91 Days (13 Weeks) of Treatment | 12.01 ± 56.22 | -6.06 ± 104.78 | 13.44 ± 49.03 | 45.62 ± 183.92 | 2.79 ± 61.44 |
At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of C-peptide concentrations. An increase from baseline to the end of treatment, a positive value, indicates an improvement.
| nmol/l | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean C-peptide Concentration After 91 Days (13 Weeks) of Treatment | 0.02 ± 0.15 | 0.09 ± 0.28 | -0.03 ± 0.18 | 0.12 ± 0.31 | 0.09 ± 0.25 |
Changes from baseline to the end of treatment in mean insulin resistance were calculated by HOMA2-IR. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin resistance, which is the reciprocal of insulin sensitivity (%S)(100/%S) as a percentage of a normal reference population (normal young adults). A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| IR score | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Insulin Resistance Measured by Homeostasis Model Assessment 2 (HOMA2-IR) After 91 Days (13 Weeks) of Treatment | 0.19 ± 1.00 | -0.19 ± 2.54 | 0.35 ± 1.20 | 0.64 ± 3.15 | 0.09 ± 1.22 |
Changes from baseline to the end of treatment in mean insulin sensitivity were calculated by HOMA2. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). An increase from baseline to the end of treatment, a positive value, indicates an improvement.
| percent sensitivity | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Insulin Sensitivity Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment | -5.26 ± 8.62 | -1.71 ± 12.62 | 1.71 ± 26.48 | 6.47 ± 27.00 | -4.07 ± 13.16 |
Changes from baseline to the end of treatment in mean insulin B Cell Function were calculated by HOMA2. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate beta cell function (%B) as a percentage of a normal reference population (normal young adults). An increase from baseline to the end of treatment, a positive value, indicates an improvement.
| percent beta function | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Insulin B Cell Function Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment | 8.13 ± 23.56 | -7.64 ± 35.00 | -1.31 ± 19.06 | 36.59 ± 70.55 | -2.41 ± 19.96 |
Body Mass Index was calculated at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| kg/m^2 | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Body Mass Index After 91 Days (13 Weeks) of Treatment | -0.38 ± 0.65 | -0.02 ± 0.72 | -0.20 ± 1.16 | -0.21 ± 1.09 | -0.50 ± 2.12 |
Subject's waist-to-hip ratios were calculated at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| ratio | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Waist-to-hip Ratio After 91 Days (13 Weeks) of Treatment | -0.00 ± 0.06 | -0.00 ± 0.04 | 0.00 ± 0.03 | -0.00 ± 0.02 | -0.01 ± 0.02 |
Subject's body weights were measured at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| kg | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Body Weight After 91 Days (13 Weeks) of Treatment | -1.05 ± 1.88 | -0.10 ± 2.07 | -0.46 ± 3.40 | -0.66 ± 3.09 | -1.64 ± 6.66 |
Subjects' waist measurements were taken at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| cm | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Waist Measurement After 91 Days (13 Weeks) of Treatment | 0.82 ± 3.90 | -0.17 ± 2.59 | 0.31 ± 4.31 | -0.39 ± 1.48 | -0.86 ± 2.55 |
Subjects' hip measurements were taken at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| cm | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Hip Measurement After 91 Days (13 Weeks) of Treatment | 1.12 ± 4.93 | 0.07 ± 2.54 | 0.38 ± 3.48 | -0.19 ± 1.30 | -0.20 ± 2.86 |
Visceral Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scans were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| litres | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Visceral Abdominal Fat After 91 Days (13 Weeks) of Treatment | 0.10 ± 0.96 | 0.62 ± 1.02 | 0.42 ± 0.87 | -0.11 ± 0.78 | 0.27 ± 1.97 |
Subcutaneous Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scans were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| litres | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Subcutaneous Abdominal Fat After 91 Days (13 Weeks) of Treatment | -0.3 ± 1.05 | 0.5 ± 0.56 | -0.0 ± 0.66 | 0.1 ± 0.84 | 0.3 ± 1.39 |
Total Abdominal Fat was measured by magnetic resonance imaging, and the results of the scans were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| litres | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Total Abdominal Fat After 91 Days (13 Weeks) of Treatment | -0.23 ± 1.53 | 1.08 ± 1.42 | 0.37 ± 1.25 | -0.05 ± 1.52 | 0.59 ± 3.24 |
Internal Non-Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| litres | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Internal Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment | -0.22 ± 1.13 | -0.75 ± 0.87 | 0.02 ± 0.62 | -0.29 ± 0.75 | -0.37 ± 0.43 |
Subcutaneous Non-Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| litres | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Subcutaneous Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment | 0.6 ± 2.98 | 0.4 ± 1.35 | 0.2 ± 1.37 | 0.8 ± 3.17 | -2.4 ± 2.45 |
Total Non-Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| litres | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Total Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment | 0.33 ± 3.81 | -0.36 ± 1.52 | 0.18 ± 1.99 | 0.56 ± 3.87 | -2.81 ± 2.37 |
Total Internal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| litres | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Total Internal Fat After 91 Days (13 Weeks) of Treatment | -0.09 ± 2.13 | 0.46 ± 0.56 | 0.40 ± 1.07 | -0.52 ± 1.29 | -0.88 ± 1.36 |
Total Subcutaneous Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| litres | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Total Subcutaneous Fat After 91 Days (13 Weeks) of Treatment | 0.22 ± 2.63 | 1.11 ± 0.78 | 0.01 ± 1.88 | 1.08 ± 3.26 | -2.44 ± 2.25 |
Total Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| litres | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Total Fat After 91 Days (13 Weeks) of Treatment | 0.13 ± 4.61 | 1.57 ± 0.46 | 0.40 ± 2.65 | 0.57 ± 4.34 | -3.31 ± 2.91 |
Abdominal Adiposity was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| litres | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Abdominal Adiposity After 91 Days (13 Weeks) of Treatment | -0.02 ± 0.08 | 0.05 ± 0.06 | -0.01 ± 0.06 | 0.01 ± 0.08 | 0.04 ± 0.10 |
Percentage liver fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment in base per cent values, a negative value, indicates an improvement.
| percent liver fat | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean % Liver Fat After 91 Days (13 Weeks) of Treatment | -1.12 ± 19.75 | 0.37 ± 7.15 | -4.73 ± 9.87 | 0.77 ± 10.56 | -2.95 ± 12.40 |
Subjects scored their appetite daily using an appetite 0-10 numerical rating scale score where 0 = no appetite (don't feel hungry) and 10 = maximum appetite (completely hungry all the time). The mean change from baseline to the end of treatment in scores were calculated. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.
| units on a scale | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Appetite 0-10 Numerical Rating Scale Score After 91 Days (13 Weeks) of Treatment | -1.19 ± 2.02 | -0.84 ± 1.96 | -0.69 ± 0.99 | -0.36 ± 2.01 | -0.59 ± 1.10 |
The incidence of treatment-emergent adverse events was recorded for the study duration, and the number of patients who experienced an adverse event is presented.
| participants | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| Adverse Events as a Measure of Patient Safety | 7 | 8 | 11 | 11 | 13 |
The BDI-II is a 21 question, multiple choice, self-reported inventory, and is one of the most widely used instruments for measuring the severity of depression. The 21 questions or items each had four possible responses. Each response was assigned a score ranging from zero to three, indicating the severity of the symptom, with a total possible score ranging from zero to 63. A score between zero and 13 indicates 'minimal depression'. A score between 14 and 19 indicates 'mild depression'. A score between 20 and 28 indicates 'moderate depression', and a score between 29 and 63 indicates 'severe depression'. As such, an increase from baseline to the end of treatment, a positive value, indicates a deterioration.
| units on a scale | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment | 0.27 ± 1.27 | 4.91 ± 8.08 | 0.85 ± 2.23 | 0.58 ± 2.15 | -0.08 ± 4.17 |
Collected over All adverse events occurring during the study (up to 133 days) were collected. All deaths and serious adverse events occurring within 28 days of the final dose of study medication were also collected.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1:1 GWP42003 : GWP42004 | — | 1/11 (9.1%) | 7/11 (63.6%) |
| 20:1 GWP42003 : GWP42004 | — | 2/12 (16.7%) | 8/12 (66.7%) |
| GWP42003 and Placebo | — | 0/13 (0%) | 11/13 (84.6%) |
| GWP42004 and Placebo | — | 0/12 (0%) | 11/12 (91.7%) |
| Placebo | — | 1/14 (7.1%) | 13/14 (92.9%) |
| Event | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| Self-injurious ideationPsychiatric disorders | 1/11 | 0/12 | 0/13 | 0/12 | 0/14 |
| Myocardial infarctionCardiac disorders | 0/11 | 1/12 | 0/13 | 0/12 | 0/14 |
| Suicidal ideationPsychiatric disorders | 0/11 | 1/12 | 0/13 | 0/12 | 0/14 |
| Myocardial ischaemiaCardiac disorders | 0/11 | 0/12 | 0/13 | 0/12 | 1/14 |
| Event | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo |
|---|---|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 1/11 | 0/12 | 2/13 | 4/12 | 2/14 |
| DiarrhoeaGastrointestinal disorders | 0/11 | 0/12 | 1/13 | 2/12 | 0/14 |
| NasopharyngitisInfections and infestations | 1/11 | 1/12 | 1/13 | 2/12 | 0/14 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/11 | 2/12 | 1/13 | 0/12 | 0/14 |
| HaematuriaRenal and urinary disorders | 0/11 | 0/12 | 0/13 | 2/12 | 2/14 |
| InfluenzaInfections and infestations | 0/11 | 1/12 | 1/13 | 1/12 | 2/14 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/11 | 0/12 | 0/13 | 0/12 | 2/14 |
| DizzinessNervous system disorders | 1/11 | 0/12 | 0/13 | 1/12 | 2/14 |
| FlatulenceGastrointestinal disorders | 1/11 | 0/12 | 1/13 | 0/12 | 0/14 |
| FatigueGeneral disorders | 1/11 | 1/12 | 0/13 | 1/12 | 1/14 |
| Age, Categorical(Participants) | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 11 | 11 | 8 | 10 | 48 |
| >=65 years | 3 | 1 | 2 | 4 | 4 | 14 |
| Age, Continuous(years) | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 59.33 ± 8.75 | 57.96 ± 8.11 | 56.80 ± 9.92 | 62.45 ± 12.58 | 58.63 ± 7.72 | 58.98 ± 9.41 |
| Sex: Female, Male(Participants) | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 5 | 3 | 3 | 2 | 7 | 20 |
| Male | 6 | 9 | 10 | 10 | 7 | 42 |
| Region of Enrollment(participants) | 1:1 GWP42003 : GWP42004 | 20:1 GWP42003 : GWP42004 | GWP42003 and Placebo | GWP42004 and Placebo | Placebo | Total |
|---|---|---|---|---|---|---|
| United Kingdom | 11 | 12 | 13 | 12 | 14 | 62 |
The record gives a start of Oct 2010, a primary completion of May 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cannabidiol · Tetrahydrocannabivarin